Melanotan II and the bodybuilding split — how a tanning research peptide became a libido drug

The Arizona lab that had been developing NDP-alpha-MSH — what became Melanotan I — was simultaneously working on related analogs with different structural properties. Melanotan II was developed as a cyclic, more lipophilic version of alpha-MSH with modifications intended to increase its potency and central nervous system penetration. Where Melanotan I was designed for selectivity at MC1R in the periphery, Melanotan II was built with properties that allowed it to cross the blood-brain barrier more readily and to bind with meaningful affinity across the melanocortin receptor family — not just MC1R, but also MC3R, MC4R, and MC5R. It was a broader tool. A more potent one. In the early days of the research, broader was not necessarily seen as a problem.

The effects of MT-II in animal models were robust. Melanogenesis, as expected. But also changes in feeding behavior, which was consistent with what was known about MC4R in the hypothalamus. And something else: in male rodents, MT-II produced a clear erectogenic response — visible penile erections in a dose-dependent fashion. This was not what the team had been looking for, but it was unmistakable in the data and impossible to ignore. The mechanistic explanation followed from what was known about MC4R's distribution: the receptor is expressed in hypothalamic nuclei that project into the spinal cord pathways controlling autonomic function, including the parasympathetic outflow that mediates erection. Stimulate those central MC4R populations and you get, among other things, downstream activation of the penile erectile response.

The self-experimentation phase — which would be considered extremely unusual by modern clinical research standards — involved a researcher at the Arizona lab administering MT-II to himself. The reported result was a prolonged and spontaneous erection, unassociated with sexual stimulation, lasting several hours. This was documented and eventually published. It became one of the more cited anecdotes in peptide research — a genuine experimental observation that confirmed the rodent data in a human system and changed the direction of subsequent development. The researcher reportedly found the experience more disconcerting than pleasant. Science is honest when the scientists are honest.

The broader implications were immediately clear to the people involved. The melanocortin system, through MC4R, was capable of initiating a sexual arousal response via a central mechanism entirely distinct from the peripheral vascular pathways that drugs like sildenafil would later target. This opened a completely different pharmacological angle on sexual dysfunction — one that operated upstream of vascular function, potentially addressing cases where the problem was not blood flow but desire and central arousal. That was a large and underserved clinical space.

The pharmaceutical industry recognized this. Palatin Technologies acquired rights to develop melanocortin peptides for sexual dysfunction and began the work of creating a more selective MC4R agonist — one that retained the central arousal effect but reduced the peripheral and off-target activity. That compound eventually became PT-141, generically named bremelanotide, which received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. It is the only centrally-acting sexual dysfunction drug approved for women in the United States, and its origin is a direct line from the Arizona MT-II observation. Bremelanotide is administered as a subcutaneous injection before anticipated sexual activity and works through the same MC4R mechanism that the original self-experiment had stumbled into.

Melanotan II itself did not follow a parallel path into formal pharmaceutical development. There are several reasons for this, and understanding them explains much about how the compound ended up where it is today. MT-II's non-selectivity — the same property that made it so pharmacologically interesting as a research tool — made it a poor drug candidate for any single indication. It produced tanning AND central effects AND appetite suppression AND nausea AND libido changes, often simultaneously. For regulatory purposes, this is not a feature. A drug that produces multiple effects at therapeutic doses needs to justify each of those effects, or demonstrate that the off-target ones are clinically acceptable, or find an indication where all the effects together constitute a benefit. MT-II didn't fit cleanly into any of those boxes. And with Palatin pursuing the selective MC4R angle and Clinuvel pursuing the selective MC1R angle, there was no remaining clear commercial rationale for developing the non-selective parent compound.

What happened instead was that MT-II entered the research-peptide market. By the late 1990s and into the 2000s, the research-peptide supply chain had developed a particular infrastructure: chemical manufacturers, mostly operating in regulatory gray zones, would synthesize compounds that existed in the published scientific literature and sell them labeled "for research use only, not for human use." The legal status of these compounds varies by country and by compound — some are controlled substances, some are unscheduled, some occupy genuinely ambiguous regulatory positions. MT-II was never approved for human use anywhere in the world, and it has no approved veterinary applications either. In most jurisdictions, the compound itself is not explicitly scheduled, but selling it as a drug for human use would be illegal. The "research only" designation is the mechanism by which these compounds circulate.

The bodybuilding community discovered MT-II early. The appeal was specific and practical: pre-competition, many competitive bodybuilders and physique athletes want to achieve maximum skin darkness to improve muscle definition under stage lighting. Self-tanning products exist, but they have an artificial quality and require precise application. A compound that produced a genuine melanin-based tan — real pigment distributed through the actual skin layers — was immediately appealing. MT-II delivered this, reliably, in weeks of use. The nausea associated with the compound was managed, in community protocols, by starting at very low doses and titrating up. The libido effects were, for many users, considered a secondary benefit rather than a concern.

The compound spread beyond bodybuilding into a broader cosmetic-tanning subculture, primarily in the United Kingdom, Australia, and parts of Europe, where tanning culture intersects with a long tradition of cosmetic peptide use. By the mid-2000s, the Melanotan II market was substantial, driven largely by online sales, and largely unregulated. The UK's Medicines and Healthcare products Regulatory Agency issued warnings about unlicensed MT-II products multiple times. Dermatologists in the UK and Australia began publishing case reports of adverse events in people who had used MT-II — skin lesion changes, unexpected pigmentation patterns, and more serious findings that will be covered separately.

The trajectory of MT-II illustrates a pattern that appears repeatedly in peptide research. A compound is developed in an academic or pharmaceutical setting for one purpose. It demonstrates unexpected effects in another domain. The pharmaceutical development takes the more tractable, selective version and runs a proper clinical program. The original, less selective compound enters the gray market and is used by people who find the combination of effects appealing, under conditions of limited safety data and no regulatory oversight. The users and the formal clinical track exist in parallel, rarely interacting, each largely unaware of the other's evidence base. What Palatin knew about bremelanotide's safety and efficacy was built in randomized controlled trials. What the MT-II community knew was built in forum posts and shared dosing logs and body-to-body n=1 experimentation. These are not equivalent sources of knowledge, and the gap between them is where most of the serious safety questions about MT-II still live.

The compound itself has not changed since Hadley's lab synthesized it. The human biology it acts on has not changed. What has changed is the context around it — and context, in pharmacology, is almost everything.